SHPHF (Sihuan Pharmaceutical Holdings Group) Long-Term Debt: $103.2 Mil (As of Dec. 2025)


SHPHF Sihuan Pharmaceutical Holdings Group Ltd SHPHF
52 GF Score
Price $0.13
GF Value $0.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sihuan Pharmaceutical Holdings Group Long-Term Debt?

Sihuan Pharmaceutical Holdings Group SHPHF 52 Long-Term Debt is $103.2 Mil as of Dec. 2025. GuruFocus rates SHPHF with a GF Score™ of 52/100 and a GF Value™ of $0.17 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sihuan Pharmaceutical Holdings Group's Long-Term Debt for the quarter that ended in Dec. 2025 was $103.2 Mil.

Sihuan Pharmaceutical Holdings Group's quarterly Long-Term Debt increased from Dec. 2024 ($102.6 Mil) to Jun. 2025 ($102.8 Mil) and increased from Jun. 2025 ($102.8 Mil) to Dec. 2025 ($103.2 Mil).

Sihuan Pharmaceutical Holdings Group's annual Long-Term Debt declined from Dec. 2023 ($129.8 Mil) to Dec. 2024 ($102.6 Mil) but then increased from Dec. 2024 ($102.6 Mil) to Dec. 2025 ($103.2 Mil).

Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sihuan Pharmaceutical Holdings Group Long-Term Debt Related Terms

Sihuan Pharmaceutical Holdings Group Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sihuan Pharmaceutical Holdings Group's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sihuan Pharmaceutical Holdings Group Long-Term Debt Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 132.63 126.62 129.79 102.59 103.21

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.79 118.44 102.59 102.78 103.21
SHPHF
52GF Score
Sihuan Pharmaceutical Holdings Group Ltd SHPHF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $103.2 Mil mean?
Sihuan Pharmaceutical Holdings Group (SHPHF) has a Long-Term Debt of $103.2 Mil as of Dec. 2025.
Is Sihuan Pharmaceutical Holdings Group's Long-Term Debt too high?
Sihuan Pharmaceutical Holdings Group's current Long-Term Debt is $103.2 Mil. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's Long-Term Debt compare to ZTS and UTHR?
Sihuan Pharmaceutical Holdings Group's Long-Term Debt of $103.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sihuan Pharmaceutical Holdings Group's current Long-Term Debt is $103.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.17, compared to a current price of $0.13 — trading 23.7% below its estimated fair value. The current Long-Term Debt is $103.2 Mil. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current Long-Term Debt is $103.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued. The current stock price of $0.13 is trading 23.7% below its estimated GF Value™ of $0.17. GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.

Key valuation signals for SHPHF:

  • Long-Term Debt: $103.2 Mil
  • GF Value™: $0.17 vs. price of $0.13 (23.7% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sihuan Pharmaceutical Holdings Group Business Description

Other Exchanges 00460:Hong KongTEL1:Germany
Address 1 Harbour Road, Convention Plaza, Room 4905, Office Tower, Wanchai, HKG
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
52GF Score

Get the complete analysis for SHPHF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$0.17
GF Value